Halfway there: Novel drug approvals and their supportive clinical trials so far in 2024

BY AMANDA CONTI

In the first half of 2024, the FDA’s Center for Drug Evaluation and Research (CDER) approved 21 novel drug products. AgencyIQ has analyzed those approvals, revealing the extent to which FDA is approving products reliant upon just a single pivotal trial – and in some cases, trials with remarkably little racial or ethnic diversity.

AgencyIQ reviews drug approvals from the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER).

Fill out the form to read the full article.